Financial Performance Highlights
Gujarat Kidney and Superspeciality Limited reported exceptional FY26 results with consolidated net profit growing 77% YoY to ₹168.12 crore and revenue doubling to ₹820.13 crore. Standalone performance showed revenue growth of 14% to ₹4010.02 lakhs and profit growth of 4% to ₹1255.70 lakhs. The company's EPS increased to ₹2.49 from ₹1.85 YoY, while current ratio improved significantly to 3.76 from 1.01, reflecting a strengthened financial position.
IPO Completion and Capital Structure
The company successfully completed its IPO in December 2025, raising ₹250.80 crore through a fresh issue of 2,20,00,000 equity shares at ₹114 per share. As of March 31, 2026, ₹205.78 crore had been utilized, with major allocations toward acquisitions (₹77 crore for Parekhs Hospital, ₹12.40 crore for Ashwini Medical Centre, ₹10.78 crore for additional stake in Harmony Medicare). Shareholders approved variation in utilization objects through postal ballot on April 25, 2026.
Business Expansion and Acquisitions
The company executed significant acquisitions including Harmony Medicare Pvt Ltd (₹155.56 crore), Parekhs Hospital Pvt Ltd (₹790.13 crore), Patel Multispeciality Hospital and ICU (₹50.00 crore), and Patel Pharmacy (₹4.40 crore). These acquisitions resulted in goodwill recognition of ₹90.73 crore. The company also made capital advances of ₹47 crore and expanded through multiple partnership arrangements.
Corporate Governance and Compliance
A corrigendum was issued to the FY26 Annual Report to include omitted Secretarial Audit qualifications and management responses. Key observations included failure to spend entire CSR amount (₹9.35 lakh required, ₹6.40 lakh spent), delay in submitting Q2 FY26 results, and failure to give prior intimation of board meetings. The company faced penalties from RoC (₹12.80 lakh), BSE (₹3.30 lakh), and NSE (₹3.30 lakh) for various compliance violations.
AGM and Corporate Actions
The 7th Annual General Meeting is scheduled for September 28, 2026, with seven resolutions proposed including appointment of directors (Anita Bharpoda, Paresh Dhoti, Disha Bharpoda), revision in remuneration for Managing Director (Pragnesh Bharpoda from ₹18 lakh to ₹36 lakh) and Whole-time Director (Bharti Bharpoda from ₹18 lakh to ₹24 lakh), and approval for borrowing limits up to ₹500 crores.
Subsidiary Structure and Related Parties
The company maintains material subsidiaries including Harmony Medicare Private Limited (100%), Raj Palmland Hospital Private Limited (51%), and Parekhs Hospital Private Limited (100%). Related party transactions include lease payments to Pragnesh Bharpoda (₹18 lakh), professional fees to Vivekkumar Patel, Nikita Bharpoda, and Pragnesh Bharpoda (₹50 lakh each), and interest expenses to Raj Palmland Hospital (₹10 lakh).
Financial Position and Ratios
The consolidated financial position shows total equity of ₹2,525.12 crore, with cash and cash equivalents of ₹132.82 crore and bank balances of ₹430.16 crore. Key ratios indicate improved liquidity (current ratio 3.76) but reduced return on equity (6.14% from 36.61%) due to the impact of IPO proceeds and acquisitions on the capital structure.